1 minute read
Feb. 9, 2022

Inavolisib: an PI3Kα Isoform-Selective Kinase Inhibitor and Mutant PI3Kα Degrader

Genentech mPI3Kα Degrader

isoform-selective mutant PI3Kα degrader oral <9 mg QD, Ph. III in HR+/HER2- BC from cellular characterization of PI3Ki and opt. inovalisib (GDC-0077) Genentech, South San Francisco, CA


Molecules of the Month

MOTY Nominees

Molecule of the Year